ID   Isreco-3
AC   CVCL_A629
SY   ISRECO-3; Isreco 3; Isreco3; ISRECO3; IS-3; IS3
DR   cancercelllines; CVCL_A629
DR   ColonAtlas; Isreco3
DR   Cosmic; 711264
DR   Cosmic; 887239
DR   Cosmic; 1479581
DR   GEO; GSM2550005
DR   Wikidata; Q54898327
RX   PubMed=9000147;
RX   PubMed=9000572;
RX   PubMed=9205061;
RX   PubMed=10766420;
RX   PubMed=11414198;
RX   PubMed=11526487;
RX   PubMed=20570890;
RX   PubMed=24042735;
RX   PubMed=25944804;
RX   PubMed=28683746;
CC   Doubling time: 69.38 hours (PubMed=25944804).
CC   Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=28683746).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=9000147; PubMed=24042735; PubMed=28683746).
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind, Guro Elisabeth.
CC   Derived from site: Metastatic; Peritoneum; UBERON=UBERON_0002358.
ST   Source(s): PubMed=24042735
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 10
ST   D19S433: 13
ST   D21S11: 31.2,32.1
ST   D2S1338: 20
ST   D3S1358: 16,18
ST   D5S818: 12,13
ST   D7S820: 9,10
ST   D8S1179: 10,12
ST   FGA: 21,22
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A627 ! Isreco-1
OI   CVCL_A628 ! Isreco-2
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 24
//
RX   PubMed=9000147;
RA   Cottu P.-H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D.,
RA   Thomas G., Hamelin R.;
RT   "Inverse correlation between RER+ status and p53 mutation in
RT   colorectal cancer cell lines.";
RL   Oncogene 13:2727-2730(1996).
//
RX   PubMed=9000572;
RA   Hoang J.-M., Cottu P.-H., Thuille B., Salmon R.J., Thomas G.,
RA   Hamelin R.;
RT   "BAT-26, an indicator of the replication error phenotype in colorectal
RT   cancers and cell lines.";
RL   Cancer Res. 57:300-303(1997).
//
RX   PubMed=9205061;
RA   Cajot J.-F., Sordat I., Silvestre T., Sordat B.;
RT   "Differential display cloning identifies motility-related protein
RT   (MRP1/CD9) as highly expressed in primary compared to metastatic human
RT   colon carcinoma cells.";
RL   Cancer Res. 57:2593-2597(1997).
//
RX   PubMed=10766420; DOI=10.1016/S0304-3835(99)00401-2;
RA   Schneider M.R., Hoeflich A., Fischer J.R., Wolf E., Sordat B.,
RA   Lahm H.;
RT   "Interleukin-6 stimulates clonogenic growth of primary and metastatic
RT   human colon carcinoma cells.";
RL   Cancer Lett. 151:31-38(2000).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11526487; DOI=10.1038/sj.onc.1204611;
RA   Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.-H.,
RA   Hamelin R.;
RT   "Extensive characterization of genetic alterations in a series of
RT   human colorectal cancer cell lines.";
RL   Oncogene 20:5025-5032(2001).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=24042735; DOI=10.1038/oncsis.2013.35; PMCID=PMC3816225;
RA   Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M.,
RA   Hektoen M., Lind G.E., Lothe R.A.;
RT   "Epigenetic and genetic features of 24 colon cancer cell lines.";
RL   Oncogenesis 2:e71.1-e71.8(2013).
//
RX   PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457;
RA   Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E.,
RA   Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R.,
RA   Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.;
RT   "Highly expressed genes in rapidly proliferating tumor cells as new
RT   targets for colorectal cancer treatment.";
RL   Clin. Cancer Res. 21:3695-3704(2015).
//
RX   PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998;
RA   Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J.,
RA   Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E.,
RA   Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.;
RT   "Multi-omics of 34 colorectal cancer cell lines -- a resource for
RT   biomedical studies.";
RL   Mol. Cancer 16:116.1-116.16(2017).
//